Roche Holding (SWX:ROP) has entered into a collaboration with C4 Therapeutics to develop degrader antibody conjugates for ...

Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third TargetC4T to Develop Degraders With ...

C4 Therapeutics (CCCC) on Thursday announced a new collaboration with its long-standing partner Roche (RHHBY) (RHHBF) to ...

C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.

Add Yahoo as a preferred source to see more of our stories on Google. Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted ...

Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...

Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...

In the first instance, Bindbridge is looking to develop a new broad spectrum non specific herbicide that can replace ...

SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation ...